Tadakazu Hisamatsu
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Objectives Ustekinumab (UST), an anti‐interleukin‐12/23 p40 monoclonal antibody, has emerged as an effective therapeutic option for patients with moderate to severe ulcerative colitis (UC). However, early predictors of long‐term treatment response remain unclear. This study aimed to assess whether 6‐month endoscopic improvement (EI) predicts sustained clinical remission (CR) in patients with UC treated with UST. Methods This was a retrospective observational study performed at Kyorin University Hospital. Patients with active UC (Lichtiger Index ≥ 5) who began UST between June 2020 and July 2023 were included. CR was assessed using the LI at weeks 4, 8, 16, and 24. EI at week 24 and sustained CR at week 56 were evaluated. Results Fifty‐seven patients were enrolled, and the CR rate at week 24 was 57.9%. CR at week 4 was significantly associated with CR at week 24 ( p = 0.004). Thirty‐one patients underwent colonoscopy at week 24. EI was achieved in 11 patients (35.5%), and patients with EI versus without EI at week 24 showed significantly higher rates of sustained CR at week 56 (90.0% sensitivity, 100.0% specificity; p = 0.005). The UST continuation rate was also significantly higher in the EI group compared with non‐EI patients ( p = 0.04). Conclusions EI 6 months after UST initiation was associated with sustained CR at week 56. This finding highlights the importance of early endoscopic assessment in optimizing long‐term outcomes in UST‐treated UC.
Year:
2026
Behçet’s disease is an autoinflammatory disorder characterized by relapsing and remitting vasculitis that can manifest in various forms, including gastrointestinal Behçet’s disease (GIBD). Its complications (e.g., intestinal perforation) are among the primary causes of morbidity and mortality. GIBD pathogenesis involves the enhanced production of certain cytokines, e.g., tumor necrosis factor α and interleukin-6 (IL-6), which could serve as a target for potential therapies. This review provides an overview of GIBD, including the diagnosis and immunopathogenesis as it is currently understood, and evaluates the emerging role of the inhibition of IL-6 (classic and trans-signaling) as an alternative treatment option for patients with GIBD. Given the current paucity of data, we reflected on the potential of IL-6 inhibitors such as tocilizumab and olamkicept based on immunopathogenic considerations and available clinical data in patients with inflammatory bowel disease (IBD), in whom clinical response or remission was induced. The selective inhibition of IL-6 trans-signaling may bring new impetus to the development of this drug class, particularly regarding safety. Still, the benefits of IL-6 inhibitors for patients with GIBD need to be evaluated in appropriate proof-of-concept studies. The clinical outcomes of IL-6 inhibitors in IBD are promising and may suggest their potential relevance in GIBD.
Year:
2025
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic condition marked by persistent intestinal inflammation of unknown etiology. Disease onset involves genetic predisposition and environmental factors that disrupt the intestinal immune homeostasis. The intestinal microbiome and immune response play pivotal roles in disease progression. Advances in molecular therapies and early interventions have reduced surgery rates; however, colorectal cancer (CRC) remains a significant concern, driven by chronic inflammation. In UC, the risk of UC-associated neoplasia (UCAN) increases with disease duration, while CD patients face elevated risks of small intestine, anal fistula, and anal canal cancers. Endoscopic surveillance is advised for UCAN, but optimal screening intervals remain undefined, and no established guidelines exist for CD-associated cancers. UCAN morphology often complicates detection due to its flat, inflammation-blended appearance, which differs pathologically from sporadic CRC (sCRC). UCAN is frequently surrounded by dysplasia, with p53 mutations evident at the dysplasia stage. IBD-associated gastrointestinal cancers exemplify inflammation-driven carcinogenesis with distinct molecular mechanisms from the adenoma-carcinoma sequence. This review explores the epidemiology, risk factors, clinical and pathological features, current surveillance practices, and molecular pathways underlying inflammation-associated cancers in IBD.
Year:
2025
Introduction: It is crucial to predict the effectiveness of advanced therapies before their administration in ulcerative colitis (UC). Only a few studies have revealed predictive histological factors. Here, we sought to determine whether conventional histology of pretreatment endoscopic biopsy specimens can predict the response to integrin inhibitors. Methods: In the present single-center retrospective study, we examined histopathological findings before initiating an integrin inhibitor. Primary response (PR) was defined as a ≥3-point decrease in the partial Mayo score at 14 weeks. Logistic regression was used to identify the factors predictive for a PR. Results: We analyzed 21 biological and Janus kinase inhibitor-naïve patients with UC. The median baseline Mayo score was 7 (IQR, 6–8), and the C-reactive protein was 0.36 (IQR, 0.11–0.74). Histological findings included large lymphoid follicles (LF) in 61.9% (13/21), basal plasma cell infiltration in 52.4% (11/21), and eosinophilic infiltration (EO) in 42.9% (9/21). PR at 14 weeks was achieved in 57.1% (12/21). Among PR patients, LF was present in 91.7% (11/12), BP in 41.7% (5/12), and EO in 25.0% (3/12). PR was observed in 76.9% (10/13) of LF-positive patients vs. 12.5% (1/8) of LF-negative patients (p = 0.01). LF was significantly associated with the response to integrin inhibitors, whereas BP and EO were not. Conclusion: The presence of LF in biopsy specimens predicts the response to integrin inhibitors in patients with UC. Conventional histological examinations may aid in predicting therapeutic responses to advanced therapies.
Year:
2025
Introduction: This final long-term extension (LTE) analysis assessed long-term efficacy and safety of ustekinumab (UST) in the Asian patient subpopulation with ulcerative colitis (UC) in the UNIFI study. Methods: Patients who completed 44 weeks of subcutaneous (SC) UST maintenance and agreed to enter the LTE continued maintenance therapy (UST 90 mg SC every 8 weeks [q8w] or 12 weeks [q12w] or placebo). The LTE lasted from week (WK) 44 through WK 220 (final safety visit), with the final efficacy visit at WK 200. At WK 56, randomized patients could receive a dose adjustment. Descriptive outcomes, such as symptomatic remission, full Mayo score outcomes, endoscopic improvement, and safety, were assessed. Results: Forty-one randomized patients entered the LTE at WK 44 and continued UST treatment (UST 90 mg SC q12w, 46.3% [19/41] or q8w, 53.7% [22/41]) through WK 188. Symptomatic remission was maintained through WK 200 (62.5% and 37.9% of patients in the UST 90 mg SC q12w and q8w groups, respectively). At WK 200, 78.9% and 50.0% of patients in the UST 90 mg SC q12w and q8w groups, respectively, were in corticosteroid-free symptomatic remission. Full Mayo clinical remission/response rates at WK 200 were 58.8%/94.1% and 75.0%/100.0% in UST 90 mg SC q12w and q8w groups, respectively (observed). Endoscopic healing rates at WK 200 in the UST 90 mg SC q12w and q8w groups were 70.6% and 91.7%, respectively (observed). No unexpected safety concerns were observed. Conclusions: Despite the small sample size which limited data interpretation, long-term UST 90 mg SC treatment is safe and efficacious in Asian patients with moderately to severely active UC demonstrating clinical benefit, consistent with the global population. In addition, Asian patients with relatively stable clinical condition may benefit from UST 90 mg SC when administered in a q12w treatment regimen given its sustained efficacy and low discontinuation rates.
Year:
2025
Introduction: Vedolizumab (VDZ) is a gut-selective integrin antagonist approved for the treatment of ulcerative colitis. While its efficacy and safety have been demonstrated in clinical trials, real-world data on long-term treatment persistence and factors associated with loss of response are limited. Methods: We conducted a retrospective single-center observational study to evaluate the persistence of treatment and factors influencing loss of response in 59 patients with ulcerative colitis treated using VDZ. Clinical outcomes, endoscopic findings, and the impact of concomitant immunomodulator or 5-aminosalicylic acid use were analyzed. Results: Thirty-two patients (54.2%) had achieved clinical remission at week 24 and 27 (45.8%) had not. The cumulative VDZ persistence rate at 3 years was 39.7%. Patients who had achieved endoscopic improvement at 24 weeks exhibited a significantly higher persistence rate. The incidence of adverse events was low (1.7%). The impact of immunomodulator and 5-aminosalicylic acid co-administration on treatment persistence was minimal. Conclusion: Endoscopic improvement at week 24 was a key predictor of long-term VDZ persistence.
Year:
2025
Color vision deficiency (CVD) may affect perception of color information in gastrointestinal endoscopy. However, the color-universal concept in endoscopy remains underappreciated. We hypothesized that image-enhanced endoscopy (IEE) could improve object/lesion visibility regardless of CVD and tested this hypothesis with volunteers of varying color vision characteristics. Sixty objects/lesions (20 each of submucosal vessels during colorectal endoscopic submucosal dissection, superficial esophageal cancer, and early gastric cancer) were evaluated. Images with WLI and IEE (red dichromatic imaging [RDI], narrow-band imaging [NBI], or indigo carmine) were assessed for each object/lesion. Twenty evaluators (9 with general color vision: Type C and 11 with two types of CVD [7 with protanopia: Type P and 4 with deuteranopia: Type D]) scored vessel and lesion visibility using a four-level scale. RDI significantly improved the visibility of submucosal vessels in Types P and D (P < 0.0001) compared with WLI, but not in Type C. NBI significantly improved visibility of superficial esophageal cancer compared with WLI in all color vision types (P < 0.0001). Indigo carmine significantly improved visibility of early gastric cancer compared with WLI in all color vision types (P < 0.0001). Although visibility scores under WLI were significantly higher in Type C compared with Types P and D for all objects/lesions, intergroup differences appeared smaller under IEE due to improved visibility in Types P and D. IEE improves visibility of objects/lesions where color information plays a role in detection, regardless of CVD.
Year:
2025
Inflammatory bowel diseases include Crohn's disease (CD) and ulcerative colitis (UC), both of which require endoscopic evaluation of mucosal surfaces. Capsule endoscopy has been used in clinical practice since 2000 as a minimally invasive means of mucosal evaluation. In Japan, there is an innovative algorithm that incorporates capsule endoscopy into the diagnostic algorithm for CD. However, capsule retention is a potential complication, and intestinal patency must be evaluated using a patency capsule or other means before capsule ingestion. In addition, the pathophysiology of CD is a combination of inflammation and stenosis, so the interpretation of score values remains an issue to be addressed. Colon capsule endoscopy for UC is useful in understanding the localization and severity of colorectal inflammation. However, capsule endoscopy is not appropriate for cancer surveillance in patients with UC, and further improvements in bowel preparation are needed. Despite these issues, capsule endoscopy, which allows noninvasive observation of mucosal surfaces, is attractive, and further development is expected.
Year:
2025
Background Fatigue is a debilitating multifactorial symptom experienced by patients with Crohn’s disease (CD). Mirikizumab, an anti-interleukin-23p19 antibody, demonstrated significant efficacy and safety in the patients with moderately to severely active CD. This analysis investigated the impact of mirikizumab on fatigue and the association between changes in clinical, endoscopic, and patient-reported outcomes with improvement in fatigue from baseline in the Phase 3 VIVID-1 study. Methods Adult patients with moderately to severely active CD that failed at least 1 biologic agent or conventional therapy were randomized to receive mirikizumab or placebo. Fatigue was assessed via the validated Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. Fatigue associations with patient-reported outcomes, endoscopic, and clinical measures were assessed via Pearson correlation analysis. Results At Week 12, 43% and 33%, and at Week 52, 46% and 36% of mirikizumab-treated patients achieved ≥ 6 and ≥ 9 fatigue score improvements vs placebo (Week 12, 31%, 22%; Week 52, 20%, 16%), respectively. Baseline fatigue scores were strongly associated with depressive symptoms and moderately associated with quality of life (QoL) at baseline. Improvements in fatigue at Weeks 12 and 52 were strongly associated with QoL and patient-reported outcomes and weakly with objective markers of inflammation and disease activity. Conclusions Mirikizumab-treated patients with CD achieved higher rates of clinically meaningful improvement in fatigue vs placebo at Weeks 12 and 52, which correlated with improvement in clinical and patient-reported outcomes. Baseline fatigue severity was strongly associated with depressive symptoms in VIVID-1 (NCT03926130).
Year:
2025
Background and Aims Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124. Obefazimod has demonstrated safety and efficacy in patients with moderate-to-severely active ulcerative colitis (UC) in a phase 2b induction trial. This analysis presents the 2-year outcome data of the open-label maintenance (OLM) study. Methods Patients received placebo or obefazimod 25, 50, or 100 mg once–daily (od) during the induction trial and, irrespective of their clinical response, could enter the 96-week OLM study with obefazimod 50 mg od. Safety was monitored through monthly visits in the first year and quarterly visits in the second year. Efficacy was assessed at weeks 48 and 96 using nonresponder imputation (NRI) for missing data. Results Of 222 eligible patients, 217 were enrolled and 164 (75.6%) completed week 96 of the OLM study. Clinical response was achieved at weeks 48 and 96 in 177 (81.6%) and 158 (72.8%) patients and clinical remission in 119 (54.8%) and 114 (52.5%) of patients. A total of 133 (61.3%) and 128 (59.0%) patients showed endoscopic improvement, and 72 (33.2%) and 78 (35.9%) endoscopic remission. In total, 148/217 patients (68.2%) reported at least 1 treatment-emergent adverse event (TEAE). The most frequent TEAEs were COVID-19 (14.3%), headache (11.5%), UC (7.8%), and nasopharyngitis (6.9%). No new safety risks emerged over 96 weeks. Conclusions The 96-week OLM study supports the long-term efficacy and favorable safety profile of obefazimod 50 mg od. A phase 3 program with obefazimod in patients with moderate-to-severe UC is ongoing. Trial registration name/number A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate-to-severe UC. NCT04023396.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (22)
Makoto Naganuma
Kansai Medical University
Javier Pérez Gisbert
Principal Investigator
Universidad Autónoma de Madrid
Hiromu Morikubo
School of Medicine, Kyorin University
Remo Panaccione
Director, Inflammatory Bowel disease Unit, Professor of Medicine
University of Calgary
Mitsuhiro Takeno
Nippon Medical School Musashi Kosugi Hospital
Raja Atreya
University Hospital Erlangen
Séverine Vermeire
University Hospitals Leuven
Britta Siegmund
-
Alessandro Armuzzi
Humanitas University
Geert D’Haens
-
Hiroshi Nakase
Dean
-
Laurent Peyrin‐Biroulet
-
Edouard Louis
University of Liege
Philippe Pinton
Senior Vice President, Global Head
Ferring Pharmaceuticals (Denmark)
Motohiro Esaki
Professor
Saga University
Kento Takenaka
Tokyo Medical and Dental University
Vipul Jairath
Professor of Medicine
Western University
Katsuyoshi Matsuoka
Professor
-
Toshifumi Hibi
-
Silvio Danese
Vita-Salute San Raffaele University
Marc Ferrante
-
Mitsuhiro Fujishiro
Professor
Nagoya University
Make your next move.
Prepare your application
Review drafts before you send them.